Purpose: Approximately 10% to 20% of patients will have a recurrence after urethroplasty. Initial management of these recurrences is often by urethral dilation or direct vision internal urethrotomy. In the current study we describe the outcomes of endoscopic management of stricture recurrence after bulbar urethroplasty. Materials and Methods: We retrospectively reviewed bulbar urethroplasty data from 5 surgeons in the TURNS (Trauma and Urologic Reconstruction Network of Surgeons). Men who underwent urethral dilation or direct vision internal urethrotomy for urethroplasty recurrence were identified. Recurrence was defined as the inability to pass a 17Fr cystoscope through the area of reconstruction. The primary outcome was the success rate of recurrence management. Comparisons were made between urethral dilation and direct vision internal urethrotomy, and then between endoscopic management of recurrences after excision and primary anastomosis urethroplasty vs substitutional repairs using time to event statistics. Results: In 53 men recurrence was initially managed endoscopically. Median time to urethral stricture recurrence after urethroplasty was 5 months. At a median followup of 5 months the overall success rate was 42%. Success after urethral dilation was significantly less than after direct vision internal urethrotomy (1 of 10 patients or 10% vs 21 of 43 or 49%, p <0.001) with a failure HR of 3.15 (p ¼ 0.03). Direct vision internal urethrotomy was more effective after substitutional failure than after excision and primary anastomosis urethroplasty (53% vs 13%, p ¼ 0.005). Conclusions: Direct vision internal urethrotomy was more successful than urethral dilation in the management of stricture recurrence after bulbar urethroplasty. Direct vision internal urethrotomy was more successful in patients with recurrence after substitution urethroplasty compared to after excision and primary anastomosis urethroplasty. Perhaps this indicates a different mechanism of recurrence for excision and primary anastomosis urethroplasty (ischemic) vs substitution urethroplasty (nonischemic).
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Materials and Methods:
We retrospectively reviewed bulbar urethroplasty data from 5 surgeons in the TURNS (Trauma and Urologic Reconstruction Network of Surgeons). Men who underwent urethral dilation or direct vision internal urethrotomy for urethroplasty recurrence were identified. Recurrence was defined as the inability to pass a 17Fr cystoscope through the area of reconstruction. The primary outcome was the success rate of recurrence management. Comparisons were made between urethral dilation and direct vision internal urethrotomy, and then between endoscopic management of recurrences after excision and primary anastomosis urethroplasty vs substitutional repairs using time to event statistics. Results: In 53 men recurrence was initially managed endoscopically. Median time to urethral stricture recurrence after urethroplasty was 5 months. At a median followup of 5 months the overall success rate was 42%. Success after urethral dilation was significantly less than after direct vision internal urethrotomy (1 of 10 patients or 10% vs 21 of 43 or 49%, p <0.001) with a failure HR of 3.15 (p ¼ 0.03). Direct vision internal urethrotomy was more effective after substitutional failure than after excision and primary anastomosis urethroplasty (53% vs 13%, p ¼ 0.005). Conclusions: Direct vision internal urethrotomy was more successful than urethral dilation in the management of stricture recurrence after bulbar urethroplasty. Direct vision internal urethrotomy was more successful in patients with recurrence after substitution urethroplasty compared to after excision and primary anastomosis urethroplasty. Perhaps this indicates a different mechanism of recurrence for excision and primary anastomosis urethroplasty (ischemic) vs substitution urethroplasty (nonischemic). The corresponding author certifies that, when applicable, a statement(s) has been included in the manuscript documenting institutional review board, ethics committee or ethical review board study approval; principles of Helsinki Declaration were followed in lieu of formal ethics committee approval; institutional animal care and use committee approval; all human subjects provided written informed consent with guarantees of confidentiality; IRB approved protocol number; animal approved project number. MALE urethral stricture disease has an incidence rate of up to 0.6% with an estimated direct cost of care of more than $200 million.
1 While urethroplasty is widely regarded as the gold standard in the management of male urethral stricture disease, the overall recurrent stricture rate after urethroplasty is between 8.3% and 18.7% depending on repair type and location. 2 While endoscopic options, including UD and/or DVIU, remain the most common initial management of these recurrences, the optimal treatment strategy in these patients remains unknown. Revision urethroplasty has a high success rate in this setting 3e5 but it is significantly more invasive than endoscopic options.
In the current study we describe the outcomes of endoscopic management of recurrent stricture after bulbar urethroplasty. Our objective was to identify the best initial strategy of endoscopic treatment of patients with recurrence after urethroplasty.
MATERIALS AND METHODS

Study Population
Between 2007 and 2014 patients from 7 institutions affiliated with the TURNS were entered into an institutional review board approved database evaluating urethroplasty outcomes. The details of this prospective database were published previously. 6 The current study includes cases of recurrent strictures after bulbar urethroplasty performed by 1 of 5 surgeons who contributed data to the combined web based database. Recurrent stricture management and outcomes data were available for all cases. The specific length of the recurrence was not recorded, although all substitution recurrences in this cohort developed at the distal and/or the proximal anastomosis and all recurrences after EPA were at the site of the original anastomosis. All EPAs were traditional transecting EPAs and nearly all substitution urethroplasties were performed with a buccal graft applied dorsally or ventrally.
Urethroplasty Recurrence Definition
We used the anatomical definition of stricture recurrence, which is that a standard 17Fr flexible cystoscope is unable to navigate past the area of reconstruction without force. 7 Standard followup included 3 and 12-month cystoscopy, and cystoscopy yearly thereafter on an as needed basis. 6 Men found to have anatomical stricture recurrence are generally offered endoscopic treatment prior to revision urethroplasty. However, men with asymptomatic recurrences will sometimes elect a watchful waiting strategy prior to any intervention, assuming that no active bladder and/or renal sequelae result. The percent of men who elected watchful waiting was determined in this study but specific followup details on these men were not analyzed.
The choice of urethral dilation or DVIU to manage recurrent stricture was left to surgeon discretion, and recurrent stricture length and caliber were not available in our database. All UDs were performed with a 24Fr balloon dilator (Cook Medical, Bloomington, Indiana or Boston Scientific, Marlborough, Massachusetts). These dilators are nonconforming and designed to handle pressures up to 20 atm. All DVIUs were performed with a cold knife. Incisions were generally made in the spongy tissue at the 4 and 8 o'clock positions. However, because recurrence characteristics are heterogeneous, other incisions were also made to accommodate stricture specific characteristics at surgeon discretion. All endoscopic procedures were followed by a short catheterization period of 3 to 7 days.
Routine followup after endoscopic repair included cystoscopy at 3 months and then every 6 months until stricture stabilization or a need for repeat urethroplasty was determined. Notably this differed from our cystoscopic followup after primary urethroplasty, given the higher suspected chance of recurrence.
Statistical Analysis
Our primary outcome was success after endoscopic treatment of stricture recurrence, defined as the ability to traverse the endoscopically managed recurrent stricture with a cystoscope without force. Subanalyses included 1) a comparison of outcomes between DVIU and UD, and 2) a comparison of DVIU outcomes for EPA and substitution recurrences. Time to event analysis was performed with Kaplan-Meier curves 8 and Cox regression models. 9 Statistical significance was considered at p <0.05. All statistical analyses were performed with IBMÒ SPSSÒ 20.
RESULTS
Demographics
A total of 130 men experienced recurrence after urethroplasty, of whom 53 (41%) elected initial endoscopic management of the recurrence. Those men were the focus of this study. Of these cases 23% developed after EPA and 77% developed after substitution urethroplasty. Notably only 4 patients (7.5%) who elected endoscopic management of recurrence were completely asymptomatic at the time of routine cystoscopy. Median time to urethral stricture recurrence after urethroplasty was 5 months (IQR 4e12). Initial endoscopic treatment was DVIU in 43 men (81%) and urethral dilation in 10 (19%). All endoscopic procedures were performed with curative intent and none was augmented with an injection of steroid or another injectable meant to modify recurrence.
Direct Visual Internal Urethrotomy versus Urethral Dilation
At a median followup of 5 months (IQR 2.1e23) 41.5% of patients in the overall cohort were free of recurrence after endoscopic treatment. The DVIU success rate was statistically higher than that of UD (48.8% vs 10%, p <0.0001).
Time to event analysis revealed significant differences in the recurrence rate between UD and DVIU (log rank p <0.001, fig. 1 ). Cox modeling revealed a threefold higher risk of failure for UD than for DVIU (HR 3.15, 95% CI 1.07e9.29, p ¼ 0.038) and a twofold higher but nonsignificant risk in patients who underwent EPA vs substitution urethroplasty (HR 2.41, 95% CI 0.99e5.85, p ¼ 0.053).
Direct Visual Internal Urethrotomy Success for Excision and Primary Anastomosis Urethroplasty versus Substitution Failures
The success rate of DVIU for substitution repairs was significantly higher than that for EPA failures (53% vs 13%). On time to event analysis DVIU was more successful after substitution urethroplasty than after EPA (log rank p ¼ 0.005, fig. 2 ).
DISCUSSION
Primary endoscopic treatment and urethroplasty are the major treatment options in patients with anterior urethral stricture disease with the latter considered the current gold standard in men with bulbar urethral strictures. 10e12 There is a high level of evidence that the 2 modalities of primary endoscopic management (UD and DVIU) have equal efficacy. 13, 14 This equivalency was reiterated in the AUA (American Urological Association) guideline on the management of male urethral strictures. 15 However, recurrent stricture disease after primary urethroplasty is considered mechanistically different in origin and it is unclear whether the mentioned equivalency extends to such patients. Specifically recurrent urethral strictures after urethroplasty tend to be more focal (at the site of previous anastomoses) and have less associated spongiofibrosis and better overall vascularity than primary urethral strictures. 16 In the current study we evaluated the outcomes of endoscopic treatment in patients with recurrence after initial bulbar urethroplasty. We found that at a mean followup of 16 months patients treated with DVIU for recurrent stricture disease after urethroplasty had a statistically significantly higher success rate than patients who underwent urethral dilation (48.8% vs 10%). In a subset of patients treated with DVIU after urethroplasty failure DVIU after substitution urethroplasty was more successful than after EPA.
While this study was not specifically designed to elucidate the reasons for differences in the success rate of endoscopic failure management, we believe that a plausible explanation may exist which could affect clinical practice. EPA involves excision of the diseased segment of the urethra and reanastomosis of healthy proximal and distal segments. This anastomosis should be under no tension and in a spatulated manner, allowing for moderate post-procedural lumen contraction without affecting the final lumen size. Therefore, assuming that the procedure was technically appropriate and all diseased urethral tissue was appropriately excised, failed repair is more likely to be related to postoperative local ischemia and, thus, it will not respond well to endoscopic repair.
On the other hand, substitution repair is quite different in that urethral transection typically does not occur. This theoretically would better preserve the local blood supply and make local ischemia a less likely cause of failure. Rather, technical concerns at the anastomotic sites and/ or under recognition of the stricture extent may be more plausible causes. Thus, an intact spongiosum at the site of failed substitution urethroplasty may portend better outcomes of endoscopic management than the failures after EPA.
Of note our 42% success rate of endoscopic management after urethroplasty failure was lower than the 50% to 70% in earlier reports.
17e19 However, these reports were single institution series, they had a small sample size of recurrence or there was no standardized definition of treatment failure. To our knowledge the current report is the largest multi-institutional analysis of the outcomes of initial endoscopic treatment in patients with recurrence after initial urethroplasty.
This study has limitations that deserve special mention. 1) This is a retrospective study of prospectively entered data and so was subject to the biases pertinent to such studies. 20 2) While the overall number of patients was small at 53 and median followup was only 5 months, this is to our knowledge the largest multi-institutional study of endoscopic management of urethroplasty recurrence.
3) The choice of whether to perform DVIU vs UD was at surgeon discretion. As described these procedures were previously found to have similar efficacy. However, given the findings in the current study, future studies of endoscopic management after urethroplasty should account for different success rates of DVIU vs dilation. 4) Not all patients with anatomical recurrence underwent treatment since many were asymptomatic (ie there was no functional recurrence). Thus, there was some selection bias and it is unclear how this affected outcomes. 5) We did not have information on recurrent stricture characteristics, including length or caliber, which may have offered even more insight into which types of recurrence were likely to be amenable to endoscopic repair.
6) While we postulated a different mechanism of failure after DVIU vs dilation, we did not have histological data such as a tissue diagnosis that might have helped elucidate tissue level metrics.
CONCLUSIONS
DVIU is superior to urethral dilation for the management of stricture recurrence after bulbar urethroplasty. DVIU is more successful in patients with recurrence after substitution urethroplasty than after EPA, perhaps indicating a different mechanism of recurrence for EPA (ischemic) vs substitution urethroplasty (nonischemic).
EDITORIAL COMMENTS
This study by Sukumar et al is a retrospective multicenter review of the records of 53 patients who underwent endoscopic treatment for stricture recurrence after bulbar urethroplasty. In this cohort based on time to event analysis endoscopic treatment was successful in 41% of patients while the success rate after DVIU was higher than after urethral dilation (49% vs 10%).
Despite the median followup of 5 months this is an important study and a relevant patient population. Bulbar urethroplasty is well established as the most successful treatment of urethral stricture but stricture recurrence is a reality even in expert hands which is more likely to develop in patients with infectious strictures, longer strictures, increased comorbidity and obesity. 1 While revision urethroplasty may have success comparable to that of primary urethroplasty, it is valuable to know that endoscopic procedures can salvage cases without the need for further open surgery (reference 4 in article). Although it was not examined in this study, it may also be worthwhile to augment the efficacy of DVIU in these patients with submucosal injection of triamcinolone. 2 All things considered, it would seem prudent to offer DVIU to patients with recurrent stricture after urethroplasty prior to pursuing revision surgery and reserve revision urethroplasty for those in whom DVIU fails or those with a long or multifocal recurrence.
One of the greatest dilemmas in urethral reconstruction is how to approach stricture recurrences after urethroplasty. Redo urethroplasty is challenging. Dissection can be difficult in the scarred tissue and an already compromised blood supply decreases the chance of a successful outcome, making endoscopic management a tempting alternative. In smaller, single institutional cohorts good success with endoscopic management has been reported but variability in technique, prior repair and success rates often left room for doubt whether this would indeed be the preferred approach. However, in the current study the large cohort, the stringent study design incorporating several centers, the systematic patient workup and data gathering allowed for extrapolation of the results to general practice.
The key findings these authors report are 1) DVIU was successful in about half of the recurrences and far superior to dilation and 2) endoscopic management with DVIU should be reserved for substitution urethroplasty as the success rate in recurrences after excision and primary anastomoses is poor. Those patients are best served by redo urethroplasty.
Using these results as a basic guideline should aid in treating and counseling patients and hopefully also alleviate some of the frustration that the patient and the urologist face in this situation.
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